Intravenous immunoglobulin treatment in a patient with adrenomyeloneuropathy.

BMC Neurol

Kennedy Centre, Copenhagen University Hospital, Rigshospitalet, Gl, Landevej 7, Copenhagen, 2600, Glostrup, Denmark.

Published: September 2012

Background: Adrenomyeloneuropathy (AMN) is one of several phenotypes of the adrenoleukodystrophy spectrum caused by mutations in the ABCD1 gene on the X chromosome. An inflammatory component is part of the disease complex ranging from severe childhood CNS demyelination to spinal cord and peripheral nerve degeneration.

Case Presentation: We present a patient with clinical progressive AMN and severe lower limb pain. Longitudinal brain magnetic resonance spectroscopy showed a constant slightly elevated myoinositol/total creatine ratio during the five year treatment period, probably reflecting demyelination, microglial activation and gliosis, indicating an inflammatory response. The pain was refractory to conventional therapy but intravenous immunoglobulin (IVIG) treatment was highly efficient.

Conclusion: IVIG may be considered as a last resort for treatment of refractory pain in AMN patients with indications of an inflammatory component.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3517486PMC
http://dx.doi.org/10.1186/1471-2377-12-108DOI Listing

Publication Analysis

Top Keywords

intravenous immunoglobulin
8
inflammatory component
8
treatment
4
immunoglobulin treatment
4
treatment patient
4
patient adrenomyeloneuropathy
4
adrenomyeloneuropathy background
4
background adrenomyeloneuropathy
4
adrenomyeloneuropathy amn
4
amn phenotypes
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!